Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.35 and traded as low as $2.31. Oramed Pharmaceuticals shares last traded at $2.33, with a volume of 30,850 shares trading hands.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, February 19th.
Check Out Our Latest Report on Oramed Pharmaceuticals
Oramed Pharmaceuticals Stock Performance
The firm has a market cap of $89.09 million, a P/E ratio of 20.09 and a beta of 1.61. The company's 50 day moving average is $2.30 and its 200 day moving average is $2.35.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.04. On average, equities research analysts anticipate that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current year.
Institutional Trading of Oramed Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the company. World Equity Group Inc. acquired a new position in shares of Oramed Pharmaceuticals in the fourth quarter valued at approximately $48,000. XTX Topco Ltd increased its position in Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 9,242 shares during the period. Marquette Asset Management LLC acquired a new position in Oramed Pharmaceuticals in the 4th quarter valued at approximately $81,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Oramed Pharmaceuticals during the third quarter valued at $272,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 70,190 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Further Reading
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
